IOVA Stock Forecast: Iovance Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.89
−5.75% on the day

The 9 Wall Street analysts covering Iovance Biotherapeutics, Inc. hold a median 12-month price target of $16 — +125.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$3.4B
Ticker Nerd rank
95/ 100
Median analyst target
$16
Analysts covering
9
Revenue$99.3M+65.7% y/y
Operating income−$51.9M
Net income−$47.3M
Free cash flow−$66.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.2%
1M
−53.6%
YTD
+152.4%
1Y
+216.1%
From 52W high
−53.6%
From 52W low
+222.0%
$2
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Iovance Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
95/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
98
Quality
97
Value
92
Momentum
91
Growth
90
Issuance
43
Accruals
37
Volatility
35

Revisions (98): Analysts have, on balance, been raising their forecasts.

Volatility (35): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IOVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IOVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26IOVAHigh $20Median $16Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7
Buy
2
Hold
0
Sell
$8
Low
$16
Median
$20
High

The green dot is the last close — the median target sits +125.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 13 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Nov 2026BarclaysMaintainsOverweight$18 → $19
6 Nov 2026CitizensMaintainsMarket Outperform$8.00 → $12
3 Nov 2026UBSMaintainsNeutral$7.00 → $8.00
13 Oct 2026BarclaysMaintainsOverweight$15 → $18
8 Oct 2026BairdMaintainsNeutral$6.00 → $11
30 Sept 2026Wells FargoMaintainsOverweight$14 → $18
29 Sept 2026HC Wainwright & Co.MaintainsBuy$9.00 → $20
24 Sept 2026Goldman SachsReinstatesBuy$15
17 Sept 2026BarclaysMaintainsOverweight$13 → $15
25 Aug 2026TD CowenMaintainsBuy$7.00 → $10
20 Aug 2026UBSMaintainsNeutral$4.00 → $7.00
18 Aug 2026MizuhoMaintainsOutperform$10 → $11
7 Aug 2026BarclaysMaintainsOverweight$11 → $13
7 Aug 2026CitizensMaintainsMarket Outperform$5.00 → $8.00
8 May 2026Chardan CapitalMaintainsBuy—
7 May 2026Chardan CapitalMaintainsBuy$16 → $14
10 Apr 2026Chardan CapitalMaintainsBuy—
5 Mar 2026UBSMaintainsNeutral—
3 Mar 2026CitizensUpgradeMarket Outperform—
25 Feb 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IOVA.

Market Radar

This page is one stock. Monday covers all of them.

IOVA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IOVA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Iovance Biotherapeutics, Inc. returned +216.1% against +6.9% for the S&P 500, dividends included.

IOVA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Jan 26Apr 26Jul 26Oct 26IOVAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IOVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
8.9×

Cheaper than 13% of US stocks

Price / book
4.1×

Cheaper than 23% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
56.1%

Higher than 69% of US stocks

Operating margin
−60.8%

Higher than 17% of US stocks

Net margin
—
Returns & dividend
Return on equity
−29.1%

Higher than 28% of US stocks

Return on assets
−15.2%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Iovance Biotherapeutics, Inc. has a market value of $3.4B and an enterprise value of $3.1B.

  • Revenue in the twelve months to 30 June 2026: $325.0M. The latest quarter grew 65.7% year on year.

  • Net income over the same four quarters: −$289.5M, a −89.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.73.

  • Free cash flow in the twelve months to 30 June 2026: −$296.4M.

  • Shares outstanding: 453.0M.

  • Iovance Biotherapeutics, Inc. employs 975 people — $333K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

IOVA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IOVAIovance Biotherapeutics, Inc.$3.4B95
VKTXViking Therapeutics, Inc.$3.1B13
ABCLAbCellera Biologics, Inc.$3.1B78
ADMAADMA Biologics, Inc.$2.9B60
ACADACADIA Pharmaceuticals, Inc.$2.9B84
VCELVericel Corp.$2.9B98
ARQTArcutis Biotherapeutics, Inc.$3.3B69

Take a look at IOVA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Iovance Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IOVA

What is the IOVA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Iovance Biotherapeutics, Inc. have a median 12-month price target of $16, with estimates ranging from $8 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IOVA stock a buy right now?

Of the 9 analysts covering Iovance Biotherapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Iovance Biotherapeutics, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IOVA?

As at 21 Nov 2026, Iovance Biotherapeutics, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (98 of 100).

Will IOVA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +125.0% from the last close, and Ticker Nerd's factor model ranks Iovance Biotherapeutics, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IOVA stock forecast for 2030?

No analyst covering Iovance Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IOVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $20 over the next 12 months.

How has IOVA stock performed over the past year?

Iovance Biotherapeutics, Inc. returned +216.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Iovance Biotherapeutics, Inc. do?

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering personalized cell therapies for solid tumor cancers. Its core technology uses autologous tumor-infiltrating lymphocytes, or TILs, which are immune cells collected from a patient’s tumor, expanded, and administered as an individualized treatment.

Company

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering personalized cell therapies for solid tumor cancers. Its core technology uses autologous tumor-infiltrating lymphocytes, or TILs, which are immune cells collected from a patient’s tumor, expanded, and administered as an individualized treatment. The company’s marketed products include Amtagvi, a TIL therapy for certain adults with advanced or metastatic melanoma, and Proleukin, an interleukin-2 product used in specified cancer treatment settings. Iovance also develops TIL-based therapies and related technologies for cancers including cervical, endometrial, head and neck, and non-small cell lung cancers, alongside programs addressing selected blood malignancies. Its activities span biopharmaceutical research, cell-therapy manufacturing, clinical development, and commercialization. By applying a patient-specific approach to immune-oncology, Iovance Biotherapeutics, Inc. occupies a specialized role in the cancer therapeutics market, linking advanced cellular medicine with treatment needs that may not be adequately addressed by conventional drug therapies.

CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D. · 975 employees · United States · https://www.iovance.com